Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery
Lead Research Organisation:
University of Liverpool
Department Name: Chemistry
Abstract
New nanomedicine approaches are being developed to significantly enhance HIV/AIDS treatments. The medicines will be aimed at targeting the virus in areas that are very diffcult for conventional drugs to reach. The work builds on previous success at the University of Liverpool and has a plan to fully engage with the public.
Publications
Zhang Haifei
(2009)
POLY 529-Water-dispersible organic nanoparticles by freeze drying
in ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
Whitehouse P
(2010)
The Application of Nanodispersions to Agriculture
in Outlooks on Pest Management
Traynor D
(2022)
Aqueous (co)polymer stabilisers for size-controlled 2-5 nm gold nanoparticle synthesis with tuneable catalytic activity
in New Journal of Chemistry
Tom McDonald (Author)
(2011)
RSC 10th International Conference on Materials Chemistry
Tatham LM
(2015)
Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.
in Therapeutic delivery
Tatham L
(2019)
Towards a Maraviroc long-acting injectable nanoformulation
in European Journal of Pharmaceutics and Biopharmaceutics
Steven Rannard (Author)
(2010)
INVITED ELRIG Meeting at AstraZeneca
Steven Rannard (Author)
(2009)
INVITED Armourers and Brasiers Forum
Steven Rannard (Author)
(2009)
INVITED British HIV Association
Steven Rannard (Author)
(2010)
INVITED Nanomedicine Conference
| Description | The research translated to further funding that led to human clinical evaluation. The nanoparticles formed using this approach are able to enhance drug uptake after oral delivery leading to options for the reduction in drug content in orally dosed therapies |
| Exploitation Route | The findings are already in human trials and have formed the basis for several global interactions (USAID funded and industry collaborations) |
| Sectors | Agriculture, Food and Drink,Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology |
| URL | https://news.liverpool.ac.uk/2017/02/17/new-nano-approach-to-hiv-therapy-presented-at-leading-conference/ |
| Description | The ability to reduce oral dose of poorly soluble compounds has attracted significant industry funding and ongoing research is aiming to form candidate therapies. Products in the agrochemical sector are also being evaluated |
| First Year Of Impact | 2015 |
| Sector | Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Cultural,Societal |
| Description | Inclusion of research outputs in PEPFAR watch list for future HIV therapies |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| URL | https://www.pepfar.gov/documents/organization/271314.pdf |
| Description | Membership of Innovate UK Emerging Technologies and Industries Steering Committee |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | British Society for Antimicrobial Chemot |
| Amount | £99,583 (GBP) |
| Organisation | British Society for Antimicrobial Chemotherapy |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Industrial Funding |
| Amount | £829,000 (GBP) |
| Organisation | Industry Partners |
| Sector | Private |
| Country | United States |
| Start | 04/2017 |
| End | 04/2019 |
| Description | Industrial Funding - Agrochemicals |
| Amount | £572,000 (GBP) |
| Organisation | Industry Partners |
| Sector | Private |
| Country | United States |
| Start | 01/2016 |
| End | 09/2019 |
| Description | MRC Funding for Imaging |
| Amount | £914,582 (GBP) |
| Funding ID | MR/K015931/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | NIH Funding from US |
| Amount | £87,922 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | |
| Description | NIH Funding from US |
| Amount | £87,922 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 10/2013 |
| End | 09/2014 |
| Description | New Nanoscale Drug Delivery Systems and their Application to HIV/AIDS treatment |
| Amount | £890,496 (GBP) |
| Funding ID | EP/I038721/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| End | 10/2015 |
| Description | Towards NanoMedicine Interventions for HIV/AIDS |
| Amount | £1,333,141 (GBP) |
| Funding ID | EP/K002201/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | US NIH R01 funding |
| Amount | $1,210,035 (USD) |
| Funding ID | R01AI114405 |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | |
| Description | USAID PEPFAR ART Simplification |
| Amount | $5,000,000 (USD) |
| Funding ID | AID-OAA-A-15-00069 |
| Organisation | United States Agency for International Development |
| Sector | Public |
| Country | United States |
| Start | 10/2015 |
| End | 09/2020 |
| Description | Brazil |
| Organisation | Federal University of Santa Maria |
| Country | Brazil |
| Sector | Academic/University |
| PI Contribution | Hosted a visiting scientist from Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina P.O. Box 476, Florianópolis, SC, 88040-900, Brazil to undertake the evaluation of novel nanomaterials intended for drug delivery strategies. The Liverpool team provided hands on training and direct research relating to in vitro immunological characterisation, in vitro drug disposition assays and physiologically-based pharmacokinetic modelling. The collaboration has resulted in two publications. |
| Collaborator Contribution | Adny Silva spent a period of 8 months at Liverpool learning various assays for pre-clinical assessment of nanomaterials that were generated by her and her colleagues in Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina P.O. Box 476, Florianópolis, SC, 88040-900, Brazil. The Brazilian collaborators therefore generated the materials and helped characterise them in Liverpool. They also co-wrote the two publications. |
| Impact | Silva AH, Locatelli C, Filippin-Monteiro FB, Martin P, Liptrott NJ, Zanetti-Ramos BG, Benetti LC, Nazari EM, Albuquerque CA, Pasa AA, Owen A, Creczynski-Pasa TB. Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. Toxicol Lett. 2016 Mar 30;246:17-27. doi: 10.1016/j.toxlet.2016.01.018. Epub 2016 Jan 25. |
| Start Year | 2014 |
| Description | EU Nanocharacterisation Laboratory |
| Organisation | University of Glasgow |
| Department | English Language |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University of Liverpool team provide critical expertise developed through EPSRC grant funded activity, to the Horizon 2020 funded European Nanocharcterisation Laboratory |
| Collaborator Contribution | Additional input from multiple EU partners to characterise candidate nanomedicines |
| Impact | No outputs as yet |
| Start Year | 2015 |
| Description | Evaluation of nanoparticles for agrochemical optimisation |
| Organisation | Nufarm |
| Country | Australia |
| Sector | Private |
| PI Contribution | Creation of new nanoscale options for agrochemical optimisation |
| Collaborator Contribution | Field trials and internal process adoption |
| Impact | Internalisation of product process and scale up of materials. Demonstration of materials benefits in global filed trials |
| Start Year | 2015 |
| Description | Evaluation of solid drug nanoparticles for pharmaceutical benefits |
| Organisation | Viiv Healthcare |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Proprietary APIs studied for nanoscale drug delivery benefits |
| Collaborator Contribution | Provision of proprietary APIs, management of the project and numerous review meetings |
| Impact | Numerous evaluations of novel materials for drug delivery |
| Start Year | 2015 |
| Description | Medicines Patent Pool |
| Organisation | Medicines Patent Pool |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | Development of prototype and clinical candidate therapies (nanomedicine) for HIV treatment |
| Collaborator Contribution | MPP are seeking partners for scale up and translation of clinical outputs to enable therapy scale up and charitable access |
| Impact | None as yet |
| Start Year | 2015 |
| Title | CHEMICAL COMPOSITION |
| Description | A solid composition comprising nanoparticles of atovaquone dispersed within one or more carrier materials, wherein the atovaquone is present in an amount of at least 10 wt%. Also described is an intramuscularly- or subcutaneously-injectable formulation of nanoparticles of atovaquone. |
| IP Reference | WO2017216564 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | First demonstration of antimalarial prophylaxis from long acting depot injection. Impact on research approaches and focus of international charities |
| Title | COMPOSITIONS OF EFAVIRENZ |
| Description | The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034925 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | No |
| Impact | The patent is supporting a human clinical trial and has initiated interest from global charities and the NIH (US) |
| Title | COMPOSITIONS OF EFAVIRENZ |
| Description | The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034925 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | Yes |
| Impact | Supporting human clinical trials |
| Title | COMPOSITIONS OF LOPINAVIR |
| Description | The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034926 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | No |
| Impact | This patent is underpinning a human clinical trial and has attracted considerable global interest from charities and NIH (US) |
| Title | COMPOSITIONS OF LOPINAVIR |
| Description | The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit- E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034926 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | Yes |
| Impact | Currently supporting human clinical trials |
| Title | COMPOSITIONS OF LOPINAVIR AND RITONAVIR |
| Description | The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol- succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034927 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | No |
| Impact | Much interest in this patent application as part of a larger portfolio and negotiations to progress to human trials are ongoing |
| Title | COMPOSITIONS OF LOPINAVIR AND RITONAVIR |
| Description | The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol- succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N- alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). |
| IP Reference | WO2013034927 |
| Protection | Patent application published |
| Year Protection Granted | 2013 |
| Licensed | Yes |
| Impact | Currently supporting human clinical trials |
| Title | NANOPARTICLES |
| Description | The present invention relates to a porous composite material comprising a hydrophilic carrier carrying a magnetic material. The porous composite material can include a hydrophobic polymer, hydrophobic material, organic compound, and/or pharmaceutically active ingredient. The porous composite material is prepared by a modified emulsion templating and freeze-drying procedure. Magnetic nanoparticles are released from the porous composite material on application of water. |
| IP Reference | WO2012143733 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | No |
| Impact | The patent application was marketed and latterly allowed to lapse |
| Title | PRODRUG COMPOSITIONS |
| Description | The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further provides processes for the making of the same. |
| IP Reference | WO2018178722 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | Engagement with global pharma companies |
| Title | Human trial of candidate nanomedicine for HIV using Efavirenz |
| Description | Human study of pharmacokinetics of orally dosed nanoparticles of efavirenz aiming at dose and pill burden reduction. Engagement with international charities (Clinton Health Access Initiative; Medicines Patent Pool, MSF) and further funding from NIH (collaboration with Johns Hopkins Medical School) and USAID (Multinational collaboration) to establish potential in other HIV related areas and malarial opportunities. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2016 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | Awaiting outcomes |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004913-41 |
| Title | Oral Nanomedicine for HIV using Lopinavir |
| Description | This is an nanomedicine for HIV therapy aiming to dramatically reduce the dose and the overall pill burden for HIV sufferers. There is also potential for paediatric therapy development. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2016 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | Licence agreement signed with UNITAID-funded Medicines Patent Pool (Geneva) and considerable additional funding to establish potential within other drugs for HIV (USAID multinational collaboration) and malaria (interatction with Johns Hopkins Medical School). In addition, significant engagement with Clinton Health Access Initiative and the securing of an R01 grant from NIH to study long acting HIV nanomedicines with a team from Johns Hopkins Medical School. |
| URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004913-41 |
| Company Name | Tandem Nano Ltd |
| Description | Tandem Nano Ltd is a nanoformulation company aiming to improve the action, delievry, use and behaviour of poorly soluble compounds |
| Year Established | 2014 |
| Impact | Currently negotiating meaningful interactions with numerous global companies |
| Website | http://www.tandemnano.com/ |
| Company Name | TANDEM NANO LTD |
| Description | The company aims to exploit nanoparticle technologies within pharmaceutical and agrochemical industries |
| Year Established | 2014 |
| Impact | The company has engaged with major multinational industries and is progressing options towards commercial exploitation |
| Description | Colorectal Therapies Healthcare Technologies Co-operative Workshop Nanoparticle-Enhanced Radiotherapy, UCL, London 27th October 2017 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dissemination and discussion of optimal approaches that may be taken for therapy options for colorectal cancer |
| Year(s) Of Engagement Activity | 2017 |
| Description | Industrial engagement in ongoing research activities |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Solid drug nanoparticle technology evaluation for industrial uptake |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Liverpool Life Sciences Network Spring Networking Event |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation and discussion with schoolchildren on Nanomedicine. Held as part of the International Society on Thrombosis and Haemostasis (ISTH) conference, BT Convention Centre, Liverpool, UK 2012 |
| Year(s) Of Engagement Activity | 2012 |
| Description | Meeting to discuss research outputs with Global Charity (Clinton Health Access Initiative) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Activity was used to engage with the Clinton Health Access Initiative to receive support and garner interest in translational activities directed at candidate global HIV nanomedicine therapy development |
| Year(s) Of Engagement Activity | 2015 |
| Description | Meeting with Industry (AZ) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | Significant interest in nanomedicine activities. Event allowed detailed engagement in discussion to evaluate future collaboration activities |
| Year(s) Of Engagement Activity | 2015 |
| Description | Meeting with industry (Revolymer) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | Engagement with research activities and future licence/collaborative research opportunities |
| Year(s) Of Engagement Activity | 2015 |
| Description | Meetings with Medicines Patent Pool (Geneva) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Discussions to evaluate licence opportunities to allow translation of research outputs through charitable funding and generic pharma companies. MPP are UNITAID funded |
| Year(s) Of Engagement Activity | 2014,2015 |
| Description | Pint of Science |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The international Pint of Science public engagement science festival aiming to communicate contemporary scientific developments to the general public in an interesting, engaging and approachable way by bringing scientists to the pub and other accessible places. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://news.liverpool.ac.uk/2017/04/03/drink-think-pint-science-festival-coming-liverpool/ |
| Description | Princes Teaching Institute CPD |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | CPD for teachers. Presentation designed to update teachers with up to date information to allow teaching knowledge in Nanomedicine |
| Year(s) Of Engagement Activity | 2014 |
| Description | Schools Outreach activity |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Vardean College/RSC Sixth former science meeting. Engagement with 6th formers to explain current progress in Nanomedicine |
| Year(s) Of Engagement Activity | 2016 |
| Description | University of Liverpool Open House |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Public engagement activity to engage public with UoL research and Nanomedicine |
| Year(s) Of Engagement Activity | 2018 |
| Description | Website for the British Society for Nanomedicine |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of the creation and launch of the British Society for Nanomedicine as website has been created allowing access to information for children, schools, the public and scientists (academic and industrial) The Society now has >300 members globally and has held multiple meetings |
| Year(s) Of Engagement Activity | 2012 |